Final Glance: Biotechnology companies
AP - Tue Aug 19, 5:09PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Amgen (AMGN) Reports Encouraging Top-Line Data on AMG 416 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 19, 4:25PM CDT
Amgen Inc. (AMGN) announced that AMG 416 has met the primary as well as secondary endpoints in the second phase III registration study.
Midday Glance: Biotechnology companies
AP - Tue Aug 19, 3:03PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
14.4% Return Seen to Date on SmarTrend Amgen Call (AMGN)
Comtex SmarTrend(R) - Tue Aug 19, 9:42AM CDT
SmarTrend identified an Uptrend for Amgen (NASDAQ:AMGN) on June 2nd, 2014 at $116.45. In approximately 3 months, Amgen has returned 14.41% as of today's recent price of $133.22.
A New Cannabinoid-based Arthritis Therapy in the Making
ACCESSWIRE - Tue Aug 19, 8:50AM CDT
WHITEFISH, MT / August 19, 2014 / Cannabinoids have been the focus of intense clinical research following the legalization of medical cannabis by several U.S. states. While pioneers like British-based GW Pharmaceuticals plc (NASDAQ: GWPH) have been actively studying cannabinoids since the 1990s, many North American companies haven't started major research until recent years with compounds just starting clinical trials.
Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company
PR Newswire - Tue Aug 19, 12:55AM CDT
Gamida Cell, a world leader in stem cell expansion technologies and therapeutic products, announced today that it has signed an investment and option agreement with Novartis Pharma AG ("Novartis"
3 Reasons Amgen, Inc.'s Stock Could Rise
Sean Williams, The Motley Fool - Motley Fool - Mon Aug 18, 5:13PM CDT
As you can see below, Amgen shareholders have had a great three years, with Amgen's stock having risen by more than 160%. AMGN data by YCharts The company's second-quarter earnings results, released three weeks ago, prove testament...
Amgen Announces Positive Top-Line Results From Second Phase 3 Study Of AMG 416 For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease Receiving Hemodialysis
PR Newswire - Mon Aug 18, 4:17PM CDT
Amgen (NASDAQ:AMGN) today announced that a second placebo-controlled Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its primary and all secondary endpoints. The primary endpoint was the proportion of patients with > 30 percent reduction from baseline in parathyroid hormone (PTH) levels during an Efficacy Assessment Phase (EAP) defined as the period between weeks 20 and 27. These results follow the recent announcement of positive data from a prior placebo-controlled Phase 3 study of AMG 416 which was similar in design and size.
Ligand Up on Multi-Program Captisol Deal with Avion Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 4:10PM CDT
Ligand Pharmaceuticals Incorporated (LGND) entered into a deal with Avion Pharmaceuticals, LLC, under which four Captisol-enabled programs will be developed and commercialized.
Earnings Look Back: Amgen Is Up 7.7% Since Reporting Quarterly Results 2 Weeks Ago (AMGN)
Comtex SmarTrend(R) - Mon Aug 18, 9:32AM CDT
20 days ago, on July 29th, 2014, Amgen (NASDAQ:AMGN) reported its earnings. Analysts, on average, expected earnings of $2.07 per share on sales of $4.9 billion. Amgen actually reported earnings of $2.37 per share on sales of $5.2 billion, beating EPS estimates by $0.30 and beating revenue estimates by $279.7 million. Shares of Amgen have climbed from $123.31 to $132.80, representing a gain of 7.7% since the company reported earnings 20 days ago.
Early Glance: Biotechnology companies
AP - Mon Aug 18, 9:29AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
The Zacks Analyst Blog Highlights: Amgen, ANN, Citi Trends, Men's Wearhouse and Kate Spade
PR Newswire - Fri Aug 15, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Amgen (Nasdaq:AMGN-Free Report), ANN Inc. (NYSE:ANN-Free Report), Citi Trends Inc. (Nasdaq:CTRN-Free Report), Men's Wearhouse Inc. (NYSE:MW-Free Report) and Kate Spade & Co. (NYSE:KATE-Free Report).
Biotech Stock Mailbag: Exact Sciences, Galena, Amgen
at The Street - Fri Aug 15, 6:22AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Global Biological Drugs Market 2014 - 2020 - Industry Analysis for the $161.056 Million Industry
M2 - Fri Aug 15, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hjz57l/biological_drugs) has announced the addition of the "Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global biological drugs market is estimated at USD 161,056.5 million in 2014 and is expected to grow at a CAGR of 10.1% from 2014 to 2020, to reach USD 287,139.7 million by 2020 The report provides in-depth analysis and estimation of the biological drugs market from 2014 to 2020, considering 2013 as the base year for calculation. Additionally, data pertaining to current market dynamics including market drivers, restraints, trends and recent developments has been provided in the biological drugs market report. The global biological drugs market is categorized based on therapeutic protein, monoclonal antibody (mAb), vaccine and geography. The therapeutic protein segmentation is further sub-segmented into Enbrel, Lantus, Neulasta, Avonex, NovoLog, Rebif, Humalog, Aranesp, Epogen, Levemir, Victoza, Betaseron, Neupogen, and Eylea. The mAb segment comprises Humira, Remicade, Rituxan, Avastin, Herceptin and Lucentis. The vaccine segment is further sub-segmented into Prevnar 13, Gardasil, Fluzone, Varivax and Cervarix. Globally, the biological drugs market is witnessing a significant growth due to increasing prevalence of various chronic diseases, as the demand for biological drugs is increasing with the rise in the global geriatric population. The biological drugs are used in the treatment and prevention of various diseases, such as blood related diseases, cancer, auto-immune diseases and other medical disorders. Additionally, various government associations are promoting the usage of biological drugs. Moreover, advancement in biomedical sciences holds immense potential for the growth of the biologic drugs market. North America is the largest market for biological drugs. Enbrel is the largest and fastest growing therapeutic protein. In monoclonal antibody (mAb), Humira is the largest and fastest growing mAb. Prevnar 13 is the largest and fastest growing vaccine. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global Biological Drugs Market - Industry Analysis Chapter 4 Market Trends Chapter 5 Porter's Five Forces Analysis Chapter 6 Global Market Size and Forecast Chapter 7 Segment Analysis, by Therapeutic Protein Chapter 8 Segment Analysis, by mAb Chapter 9 Segment Analysis, by Vaccine Chapter 10 Regional Analysis Chapter 11 Pipeline Biologic Drugs Chapter 12 Competitive Landscape Chapter 13 Company Profiles - Abbott Laboratories - Amgen Inc. - Baxter International Inc. - Biogen Idec - Bristol-Myers Squibb Company - Eli Lilly and Company - GlaxoSmithKline plc. - Merck & Co., Inc. - Novartis AG - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/hj...ical_drugs
Amgen's FOCUS Study on Multiple Myeloma Drug Kyprolis Fails - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 4:20PM CDT
Amgen (AMGN) suffered a major setback when its phase III study, FOCUS on multiple myeloma treatment, Kyprolis did not meet its primary endpoint.
After Yesterday's Rally of 3.55% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Aug 14, 3:39PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $124.81 to a high of $132.52. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $128.00 on volume of 6.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.